The medical records of 1312 patients receiving irinotecan based chemotherapy at Renmin Hospital of Wuhan University from May 2014 to May 2019 were collected. A retrospective analysis of 612 patients was finalized according to the inclusion and exclusion criteria below.
The inclusion criteria were as follows: Patients ≥ 18 years old; normal range of white blood cell (WBC) and absolute neutrophil count (ANC) tests at baseline before chemotherapy; conduction of follow-up laboratory data adequate for assessing neutropenia; and reasonable prescription of irinotecan. The exclusive criteria were: liver and kidney trans-plantation prior to the onset of neutropenia; neutropenia induced by other drugs before chemotherapy; and disease of blood and hematopoietic system such as leukemia, thrombocytopenic purpura, and so on.
The chemotherapy regimens and dose of irinotecan in this study: irinotecan alone (125mg/m2, d1, d8, d15, and d22, repeated every 6 weeks; 350mg/m2, dL, repeated every 3 weeks), irinotecan plus 5-Fluorouracil (180mg/m2, dL, repeated every 2 weeks), irinotecan plus capecitabine (250 mg/m2, dL, repeated every 3 weeks), irinotecan plus cisplatin (60mg/m2, dL, d8, and d15, repeated every 4 weeks; 65mg/m2, dL, d8, and d15, repeated every 3 weeks), irinotecan plus lobaplatin (80 mg/m2 or 90mg/m2, dL, d8, repeated every 3 weeks), irinotecan plus nedaplatin (60mg/m2 or 65mg/m2, dL, d8, repeated every 3 weeks), irinotecan plus bevacizumab (125mg/m2, dL, repeated every 2 weeks) and irinotecan plus raltitrexed (150 or 180mg/m2, dL, repeated every 2 weeks; 240mg/m2, dL, repeated every 3 weeks). Dose and schedule of irinotecan was modified according to patient age, medical condition and the combination with other anticancer drugs by each attending physician decision.
The inclusion criteria were as follows: Patients ≥ 18 years old; normal range of white blood cell (WBC) and absolute neutrophil count (ANC) tests at baseline before chemotherapy; conduction of follow-up laboratory data adequate for assessing neutropenia; and reasonable prescription of irinotecan. The exclusive criteria were: liver and kidney trans-plantation prior to the onset of neutropenia; neutropenia induced by other drugs before chemotherapy; and disease of blood and hematopoietic system such as leukemia, thrombocytopenic purpura, and so on.
The chemotherapy regimens and dose of irinotecan in this study: irinotecan alone (125mg/m2, d1, d8, d15, and d22, repeated every 6 weeks; 350mg/m2, dL, repeated every 3 weeks), irinotecan plus 5-Fluorouracil (180mg/m2, dL, repeated every 2 weeks), irinotecan plus capecitabine (250 mg/m2, dL, repeated every 3 weeks), irinotecan plus cisplatin (60mg/m2, dL, d8, and d15, repeated every 4 weeks; 65mg/m2, dL, d8, and d15, repeated every 3 weeks), irinotecan plus lobaplatin (80 mg/m2 or 90mg/m2, dL, d8, repeated every 3 weeks), irinotecan plus nedaplatin (60mg/m2 or 65mg/m2, dL, d8, repeated every 3 weeks), irinotecan plus bevacizumab (125mg/m2, dL, repeated every 2 weeks) and irinotecan plus raltitrexed (150 or 180mg/m2, dL, repeated every 2 weeks; 240mg/m2, dL, repeated every 3 weeks). Dose and schedule of irinotecan was modified according to patient age, medical condition and the combination with other anticancer drugs by each attending physician decision.
